Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Intensive Care Medicine
Published in:

Open Access 22-08-2024 | CAR T-Cell Therapy | Narrative Review

Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities

Authors: Torsten Schroeder, Tjark Martens, Lars Fransecky, Thomas Valerius, Natalie Schub, Christiane Pott, Claudia Baldus, Friedrich Stölzel

Published in: Intensive Care Medicine | Issue 9/2024

Login to get access

Abstract

The use of chimeric antigen receptor T (CAR-T) cells is a significant therapeutic improvement increasing the prognosis for patients with a variety of hematological malignancies. However, this therapy has also sometimes life-threatening, complications. Therefore, knowledge of the treatment and management of these complications, especially in treatment centers and intensive care units, respectively, is of outstanding importance. This review provides recommendations for the diagnosis, management, and treatment of CAR-T cell-associated complications such as cytokine release syndrome, immune effector cell associated neurotoxicity syndrome, hematotoxicity, hypogammaglobulinemia, and CAR-T cell-induced pseudo-progression amongst others for physicians treating patients with CAR-T cell-associated complications and intensivists.
Appendix
Available only for authorised users
Literature
1.
Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer Immunotherap Sci 342(6165):1432–1433
2.
3.
4.
Azoulay É, Castro P, Maamar A et al (2021) Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematol 8(5):e355–e364PubMedCrossRef
5.
6.
7.
Garcia Borrega J, Gödel P, Rüger MA et al (2019) In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy. Hemasphere 3(2):191–200CrossRef
8.
Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci. 2019;20(6).
9.
Pietrobon V, Todd LA, Goswami A, Stefanson O, Yang Z, Marincola F. Improving CAR T-Cell Persistence. Int J Mol Sci. 2021;22(19).
10.
Honikel MM, Olejniczak SH. Co-Stimulatory Receptor Signaling in CAR-T Cells. Biomolecules. 2022;12(9).
11.
Cappell KM, Kochenderfer JN (2021) A comparison of chimeric antigen receptors containing CD28 versus 4–1BB costimulatory domains. Nat Rev Clin Oncol 18(11):715–727PubMedCrossRef
12.
13.
Zhang X, Zhu L, Zhang H, Chen S, Xiao Y (2022) CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front Immunol 13:927153PubMedPubMedCentralCrossRef
14.
Cameron J Turtle L-AH, Carolina Berger, Daniel Sommermeyer, Barbara Pender, Emily M Robinson, Katherine Melville, Tanya M Budiarto, Natalia N Steevens, Colette Chaney, Sindhu Cherian, Brent L Wood, Lorinda Soma, Xueyan Chen, Shelly Heimfeld, Michael C Jensen, Stanley R. Riddell, David G Maloney. Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. Blood. 2015;Volume 126(Issue 23):Page 3773.
15.
Bracci L, Moschella F, Sestili P et al (2007) Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 13(2 Pt 1):644–653PubMedCrossRef
16.
Hay KA, Gauthier J, Hirayama AV et al (2019) Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133(15):1652–1663PubMedPubMedCentralCrossRef
17.
Spooren A, Kolmus K, Laureys G et al (2011) Interleukin-6, a mental cytokine. Brain Res Rev 67(1–2):157–183PubMedCrossRef
18.
Schuster SJ, Maziarz RT, Rusch ES et al (2020) Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv 4(7):1432–1439PubMedPubMedCentralCrossRef
19.
Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 25(4):625–638PubMedCrossRef
20.
Kotch C, Barrett D, Teachey DT (2019) Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol 15(8):813–822PubMedPubMedCentralCrossRef
21.
Heinz WJ, Buchheidt D, Christopeit M et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96(11):1775–1792PubMedPubMedCentralCrossRef
22.
Wang L, Lv Y, Zhou L et al (2024) Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies. Exp Hematol Oncol 13(1):1–5CrossRef
23.
Luo H, Wang N, Huang L et al (2019) Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. J Immunother Cancer 7(1):271PubMedPubMedCentralCrossRef
24.
Topp M, Van Meerten T, Houot R, et al. Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma. Blood. 2019;134(Supplement_1):243–243.
25.
Jain MD, Smith M, Shah NN (2023) How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 141(20):2430–2442PubMedPubMedCentral
26.
Cecconi M, Parsons AK, Rhodes A (2011) What is a fluid challenge? Curr Opin Crit Care 17(3):290–295PubMedCrossRef
27.
Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. Jama. 1995;274(8):639–644.
28.
Gazeau N, Liang EC, Wu QV et al (2023) Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther 29(7):430–437PubMedPubMedCentralCrossRef
29.
Garfall AL, Lancaster E, Stadtmauer EA et al (2016) Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. Blood 128(22):5702–5703CrossRef
30.
31.
Rees JH. Part IV: Clinical Management of Patients Treated with CAR-T Cells. In: Kröger N. The EBMT/EHA CAR-T Cell Handbook.2022.
32.
Patel S, Maria-Rios J, Parikh A, Okorie ON (2023) Diagnosis and management of elevated intracranial pressure in the emergency department. Int J Emerg Med 16(1):72–91PubMedPubMedCentralCrossRef
33.
Möhn N, Bonda V, Grote-Levi L et al (2022) Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. Neurol Res Pract 4(1):1PubMedPubMedCentralCrossRef
34.
Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112(10):3959–3964PubMedCrossRef
35.
Lemoine J, Vic S, Houot R (2022) Disease-specific outcomes after chimeric antigen receptor T-cell therapy. Eur J Cancer 160:235–242PubMedCrossRef
36.
37.
Wehrli M, Gallagher K, Chen YB, et al. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer. 2022;10(1).
38.
Cohen AD, Parekh S, Santomasso BD et al (2022) Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 12(2):32PubMedPubMedCentralCrossRef
39.
Wang Q, Gao J, Wu X (2018) Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol 58:125–135PubMedCrossRef
40.
Frelaut M, du Rusquec P, de Moura A, Le Tourneau C, Borcoman E (2020) Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. BioDrugs 34(4):463–476PubMedCrossRef
41.
Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143–e152PubMedPubMedCentralCrossRef
42.
Boursier C, Perrin M, Bordonne M, Campidelli A, Verger A (2022) Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma. Clin Nucl Med 47(2):e152–e153PubMedCrossRef
43.
Denton CC, Gange WS, Abdel-Azim H et al (2020) Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. Blood Adv 4(10):2158–2162PubMedPubMedCentralCrossRef
44.
45.
46.
Dunleavy K, Hakim F, Kim HK et al (2005) B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 106(3):795–802PubMedPubMedCentralCrossRef
47.
Fried S, Avigdor A, Bielorai B et al (2019) Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant 54(10):1643–1650PubMedCrossRef
48.
Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 380(1):45–56PubMedCrossRef
49.
Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol 20(1):31–42PubMedCrossRef
50.
Rejeski K, Subklewe M, Aljurf M et al (2023) Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood 142(10):865–877PubMedCrossRef
51.
Rejeski K, Perez A, Sesques P et al (2021) CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood 138(24):2499–2513PubMedPubMedCentralCrossRef
52.
Wang Y, Song Z, Geng Y et al (2022) The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy. Front Oncol 12:987965PubMedPubMedCentralCrossRef
53.
Miller KC, Johnson PC, Abramson JS et al (2022) Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J 12(10):146PubMedPubMedCentralCrossRef
54.
Davis JA, Sborov DW, Wesson W et al (2023) Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther 29(9):567–571PubMedCrossRef
55.
56.
Gagelmann N, Wulf GG, Duell J et al (2023) Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study. Blood Adv 7(4):555–559PubMedCrossRef
57.
Wat J, Barmettler S (2022) Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions. J Allergy Clin Immunol Pract 10(2):460–466PubMedCrossRef
58.
Kampouri E, Walti CS, Gauthier J, Hill JA (2022) Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Rev Hematol 15(4):305–320PubMedCrossRef
59.
Wudhikarn K, Palomba ML, Pennisi M et al (2020) Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J 10(8):79PubMedPubMedCentralCrossRef
60.
Bhoj VG, Arhontoulis D, Wertheim G et al (2016) Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood 128(3):360–370PubMedPubMedCentralCrossRef
61.
Hill JA, Seo SK (2020) How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 136(8):925–935PubMedPubMedCentralCrossRef
62.
Topp M, Feuchtinger T. Part IV Clinical Management of Patients Treated with CAR-T Cells. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H. The EBMT/EHA CAR-T Cell Handbook2022.
63.
Hill JA, Li D, Hay KA et al (2018) Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 131(1):121–130PubMedPubMedCentralCrossRef
64.
Park JH, Romero FA, Taur Y et al (2018) Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells. Clin Infect Dis 67(4):533–540PubMedCrossRef
65.
Hines MR, Knight TE, McNerney KO et al (2023) Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther 29(7):438.e431-438.e416
66.
Sandler RD, Tattersall RS, Schoemans H et al (2020) Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol 11:524PubMedPubMedCentralCrossRef
67.
Henter JI, Horne A, Aricó M et al (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131PubMedCrossRef
68.
Bergsten E, Horne A, Aricó M et al (2017) Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 130(25):2728–2738PubMedPubMedCentralCrossRef
69.
Marar RI, Abbasi MA, Prathivadhi-Bhayankaram S et al (2023) Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. JCO Oncol Pract 19(6):331–342PubMedCrossRef
70.
Nenna A, Carpenito M, Chello C, et al. Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment. Int J Mol Sci. 2022;23(15).
71.
Ganatra S, Dani SS, Yang EH, Zaha VG, Nohria A (2022) Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer. JACC CardioOncol 4(5):616–623PubMedPubMedCentralCrossRef
72.
Flugel CL, Majzner RG, Krenciute G et al (2023) Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol 20(1):49–62PubMedCrossRef
73.
74.
Cohen AD, Mateos MV, Cohen YC et al (2023) Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 141(3):219–230PubMedCrossRef
Metadata
Title
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities
Authors
Torsten Schroeder
Tjark Martens
Lars Fransecky
Thomas Valerius
Natalie Schub
Christiane Pott
Claudia Baldus
Friedrich Stölzel
Publication date
22-08-2024
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 9/2024
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-024-07576-4

Other articles of this Issue 9/2024

Intensive Care Medicine 9/2024 Go to the issue

Correspondence

Don’t oversimplify the EEG

Correspondence

Striving for perfection: navigating the complexity of extracorporeal membrane oxygenation and positioning in acute respiratory distress syndrome treatment. Author’s reply

Correspondence

Oxygen thresholds in critically ill patients: need for personalized targets. Author’s reply

Original

Conservative or liberal oxygen targets in patients on venoarterial extracorporeal membrane oxygenation

Conference Reports and Expert Panel

Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement

Editorial

Using the helmet

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

Adding radium-223 to first-line enzalutamide significantly improves the survival of patients with bone metastatic castration-resistant prostate cancer.

Read more

AI model can predict tumor mutations

No OS benefit of adding preoperative CRT in gastric cancer

T-DXd supported for breast cancer with brain metastases

» View more highlights on the ESMO 2024 hub page

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

  • Webinar | 01-10-2024 | 12:30 (CEST)

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Get a reminder for the on-demand version
Image Credits